Emerging Role of Dual Agonists in Metabolic Disease Management: Clinical Outcomes and Safety Considerations – A Review Study

Metabolic diseases, including type 2 diabetes mellitus (T2DM) and obesity, represent interconnected chronic conditions driven by complex neuroendocrine and metabolic dysregulation. Recent pharmacological advances have introduced dual incretin receptor agonists that simultaneously target glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) pathways, offering enhanced therapeutic potential beyond conventional mono-agonist therapies. This review synthesises qualitative thematic evidence from major clinical trials, mechanistic studies, and real-world observational research to evaluate the clinical effectiveness and safety considerations of dual agonists in metabolic disease management. Guided by neuroendocrine integration theory, metabolic flexibility frameworks, and chronic disease systems models, the review explores how dual agonists improve glycemic control, promote substantial weight loss, and modify cardiometabolic risk factors. Thematic synthesis indicates that synergistic hormonal modulation enhances appetite regulation, insulin sensitivity, and adipose tissue remodelling, while adverse effects remain largely gastrointestinal and manageable through dose-escalation strategies. Policy implications regarding cost, access, and preventive pharmacotherapy are discussed alongside biotechnology innovations such as multi-agonist drug design and personalised metabolic medicine. Overall, dual agonists represent a transformative therapeutic class with significant implications for integrated metabolic disease management. Keywords: Dual agonists; GLP-1; GIP; metabolic disease; obesity; type 2 diabetes; incretin therapy